{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:18:42Z","timestamp":1791494322064,"version":"4.3.4"},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.mayocp.2024.08.026","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T05:54:13Z","timestamp":1741326853000},"page":"647-656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Prescribing Patterns of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Patients With Type 2 Diabetes at Cardiology, Endocrinology, and Primary Care Visits"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7560-9521","authenticated-orcid":false,"given":"Dave L.","family":"Dixon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2708-7145","authenticated-orcid":false,"given":"Teresa M.","family":"Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7248-4890","authenticated-orcid":false,"given":"Tyler D.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haroon","family":"Hyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri T.","family":"Musselman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonya M.","family":"Buffington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9159-4876","authenticated-orcid":false,"given":"Roy T.","family":"Sabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.mayocp.2024.08.026_bib2","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.mayocp.2024.08.026_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2024.08.026_bib4","first-page":"S86","article-title":"9. Cardiovascular disease and risk management","volume":"41","year":"2018","journal-title":"Standards of Medical Care in Diabetes-2018. Diabetes Care"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2024.08.026_bib5","first-page":"S90","article-title":"9. Pharmacologic approaches to glycemic treatment","volume":"42","year":"2019","journal-title":"Standards of Medical Care in Diabetes-2019. Diabetes Care"},{"issue":"18","key":"10.1016\/j.mayocp.2024.08.026_bib6","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"5S","key":"10.1016\/j.mayocp.2024.08.026_bib7","first-page":"S1","article-title":"KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.mayocp.2024.08.026_bib8","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.mayocp.2024.08.026_bib9","article-title":"National trends in use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists by cardiologists and other specialties, 2015 to 2020","volume":"11","author":"Adhikari","year":"2022","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"13","key":"10.1016\/j.mayocp.2024.08.026_bib10","article-title":"Contemporary national patterns of eligibility and use of novel cardioprotective antihyperglycemic agents in type 2 diabetes mellitus","volume":"10","author":"Nargesi","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"25","key":"10.1016\/j.mayocp.2024.08.026_bib11","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1016\/j.jacc.2018.08.2202","article-title":"Prescriber patterns of SGLT2i after expansions of U.S. Food and Drug Administration labeling","volume":"72","author":"Vaduganathan","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.mayocp.2024.08.026_bib12","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.jacc.2019.01.029","article-title":"Prescription of glucagon-like peptide-1 receptor agonists by cardiologists","volume":"73","author":"Vaduganathan","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.mayocp.2024.08.026_bib13","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1177\/2047487317729252","article-title":"Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: an NCDR\u00d5 Research to Practice project","volume":"24","author":"Arnold","year":"2017","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"10.1016\/j.mayocp.2024.08.026_bib14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/jamacardio.2022.3839","article-title":"Use of sodium-glucose cotransporter 2 inhibitors and glucagonlike peptide-1 receptor agonists in patients with diabetes and cardiovascular disease in community practice","volume":"8","author":"Nanna","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"9596","key":"10.1016\/j.mayocp.2024.08.026_bib15","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.mayocp.2024.08.026_bib16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.amjcard.2023.03.002","article-title":"Persistence on novel cardioprotective antihyperglycemic therapies in the United States","volume":"196","author":"Nargesi","year":"2023","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.mayocp.2024.08.026_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.6139","article-title":"Association of race\/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US","volume":"4","author":"Eberly","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.mayocp.2024.08.026_bib18","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/jama.2022.13885","article-title":"Association of race and ethnicity with prescription of SGLT2 inhibitors and GLP1 receptor agonists among patients with type 2 diabetes in the Veterans Health Administration System","volume":"328","author":"Lamprea-Montealegre","year":"2022","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.mayocp.2024.08.026_bib19","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.jacc.2019.08.014","article-title":"Therapeutic inertia in cardiovascular disease prevention: time to move the bar","volume":"74","author":"Dixon","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619624004634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619624004634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:34:41Z","timestamp":1743986081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619624004634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0025619624004634"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2024.08.026","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prescribing Patterns of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Patients With Type 2 Diabetes at Cardiology, Endocrinology, and Primary Care Visits","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2024.08.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}